Relay Therapeutics

RLAYNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$4.240 B

$19.35 +6.38%

Close of 22 Sept 2026

Revenue

$15.4M

#3067 by revenue

Earnings

-$276.5M

Loss-making

Shares outstanding

219,141,631

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#23Iovance BiotherapeuticsIOVA$4.82B
#24Adaptive BiotechnologiesADPT$4.48B
#25Relay TherapeuticsRLAY$4.24B
#26Tarsus PharmaceuticalsTARS$3.61B
#27Denali TherapeuticsDNLI$3.45B

What if Relay Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$137,965.43

Per share 7,130× higher

Bitcoin $1.74T

$7,947.62

Per share 411× higher

Nvidia $5.52T

$25,169.87

Per share 1,301× higher

Or at a round number

$10.0B $20.0B $50.0B $100.0B

Where these numbers come from

Share counts and financials for Relay Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.